HALO - Halozyme gains as U.S. and EU clear Enhanze-based products
2024-01-16 12:40:46 ET
More on Halozyme Therapeutics
- Halozyme Q3: Navigating The Ups And Downs Of Its Innovative Pathway
- Halozyme Therapeutics, Inc. (HALO) Q3 2023 Earnings Call Transcript
- Halozyme Therapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation
- JNJ multiple myeloma therapy outperforms standard of care by 58%
- argenx slips as autoimmune disorder therapy fails in pivotal trial
For further details see:
Halozyme gains as U.S. and EU clear Enhanze-based products